Registration of pharmaceuticals requires a comprehensive genotoxicity evaluation. Genotoxicity is assessed following the advice on study timing relative to clinical development given in the ICH guidance M3(R2) Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. According to this guideline, in vitro tests to evaluate mutations and chromosome damage are required prior to first human exposure. If findings are positive or equivocal, additional testing must be performed. The standard battery of genotoxicity tests (ICH Topic S2) must be completed prior to initiating Phase II studies.
Besides ICH M3(R2), ICH guidance S2(R1) provides drug sponsors with recommendations on which tests should be performed to assess potential genotoxicity of new pharmaceuticals throughout their preclinical development. Vivotecnia provides a full genotoxicity testing service in compliance with these guidelines and also offers advice on testing conditions, data interpretation, and follow-up strategies should an in vitro assay give a positive response. Our services ensure that your compound’s potential to cause genetic damage is suitably tested in compliance with regulatory requirements.
Genotoxicity testing of pharmaceuticals
Test battery Option 1:
- Gene mutation test in bacteria.
- Cytogenetic test for chromosomal damage (in vitro metaphase chromosome aberration test or in vitro micronucleus test), or an in vitro mouse lymphoma Tk gene mutation assay.
- In vivo genotoxicity test, generally a test for chromosomal damage using rodent hematopoietic cells, either for micronuclei or for chromosomal aberrations in metaphase cells. (Can be integrated into repeat tox studies if a suitable dose is used.)
Testing battery Option 2:
- Gene mutation test in bacteria.
- In vivo genotoxicity assessment with two different tissues, usually an assay for micronuclei using rodent hematopoietic cells and a second in vivo assay. Typically, this would be a DNA strand breakage assay in liver, unless otherwise justified. (Can be integrated into repeat tox studies if a suitable dose is used.)
- Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, ICH M3(R2), June 2009
- Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, ICH M7(R1), March 2017
- Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use, ICH S2(R1), November 2011
Our team and Experience
Vivotecnia provides services and solutions to assist pharmaceutical, chemical, cosmetics and other industries in optimizing compound development by testing genotoxicity. With Vivotecnia’s testing packages you are sure of complying with regulatory guidelines and GLP standards and can rely on our scientific team’s vast experience (having conducted hundreds of assays) to accurately and reliably assess your compound for genotoxicity. Vivotecnia can also provide assays and advice on follow-up strategies for mechanism elucidation (e.g. clastogenicity, aneugenicity or DNA effects like frameshifts or transverse and transition mutations).
Our team will discuss your project’s specific needs with you and provide detailed assay documentation and data reporting in compliance with our internal standard operating procedures.
Our staff is fully qualified, meaning that you will receive very efficient and cost-effective service. Moreover, our team of experts is trained to troubleshoot all aspects of genotoxicity testing and can guide you on assay design and performance to yield the best data for your compound.
For more information or a formal quotation, please send us a message and we will contact you as soon as possible.
You may also be interested in …
PK/PD and Metabolism
During the drug discovery process, ADME (absorption, distribution, metabolism, and excretion) and PK studies are deemed necessary to evaluate bioavailability…
Inhalation toxicity studies are required to assess exposure hazards of consumer products or to manufacturing workers.
Our team of experienced, highly-educated scientists, experts in toxicology, molecular biology, chemistry, and immunology fully understands that the drug development process is distinct for each approach.